The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback